Alnylam Pharmaceuticals Inc

This innovative biotech stock has helped transform RNAi into an innovative new class of medicine. You have probably heard about RNA and mRNA innovation as the basis for the COVID-19 vaccine. This novel technology is set to shake up the medical world, and Alnylam is well-positioned to benefit from it.

$269.86
(as of Feb 10, 12:02 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Alnylam Pharmaceuticals Inc

Stock Price
$269.87
Ticker Symbol
ALNY
Exchange
NASDAQ

Industry Information for Alnylam Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Alnylam Pharmaceuticals Inc

Country
USA
Full Time Employees
2,100

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamentals for Alnylam Pharmaceuticals Inc

Market Capitalization
$35,623,264,256
EBITDA
$-132,146,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
909.09
Earnings per Share
$-2.62
Earnings per Share Estimate Next Year
$0.63
Profit Margin
-15.86%
Shares Outstanding
128,981,000
Percent Owned by Insiders
4.09%
Percent Owned by Institutions
97.61%
52-Week High
$304.39
52-Week Low
$141.98

Technical Indicators for Alnylam Pharmaceuticals Inc

50-Day Moving Average
$253.70
200-Day Moving Average
$237.71
RSI
60.15
9.19

Analyst Ratings for Alnylam Pharmaceuticals Inc

Strong Buy
11
Buy
11
Hold
8
Sell
1
Strong Sell
1

News About Alnylam Pharmaceuticals Inc

Feb 7, 2025, 10:00 AM EST
Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. See more.
Feb 6, 2025, 10:01 AM EST
Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. See more.
Feb 6, 2025, 9:40 AM EST
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. See more.
Feb 4, 2025, 11:36 AM EST
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. See more.
Feb 3, 2025, 10:53 AM EST
Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). See more.